



ASX / Media Release
18th May 2016

Michael Warrener Appointed Global Sales and Marketing Director

Sydney, Australia, 18 May 2016: OncoSil Medical Limited (ASX: OSL) (**OncoSil Medical** or the **Company**) is pleased to announce the appointment of Mr Michael Warrener as Global Sales and Marketing Director. Mr Warrener will be responsible for implementing the Company's commercialisation strategy and infrastructure.

Mr Warrener will be based in Sydney and will oversee the initial market launch in Europe, Australia and key Asian markets. Mr Warrener will commence his role on the 1st of June and his appointment completes the Senior Leadership Team of the Company.

Mr Warrener has forged a highly successful career in the pharmaceutical and medical device sector over a period of more than 23 years, including eight years with Sirtex Medical Ltd (ASX: SRX). During his time with Sirtex he held a number of senior management roles including Sales and Marketing Director for Europe and Middle East where he helped introduce and then drive adoption of the Sir-Spheres product in the Australian, European Union and Middle East markets. During his tenure the company achieved several positive reimbursement and sales outcomes in Europe and other jurisdictions.

Prior to joining OncoSil, Mr Warrener was Sales and Marketing Director for Australian cancer-focused medical device company, Sirtology Pty Ltd where he was responsible for commercialisation of its lead product, including regulatory submissions in Europe and the United States.

Mr Warrener has a Bachelor of Science degree from University of Sydney and Master of Business in Marketing from the University of Technology Sydney.

Commenting on the appointment, OncoSil Medical CEO, Mr Daniel Kenny said:

"We are excited to appoint Michael Warrener to the pivotal role of Global Sales and Marketing Director. As we progress through the regulatory process, we are working in parallel to advance our sales and marketing infrastructure, and Michael's appointment is a key part of this strategy. His relevant and senior level experience in the medical device sector in introducing a new brachytherapy device for cancer and building adoption and reimbursement makes him a key addition to our leadership team."

I look forward to working with Michael as we pursue our goal to commercialise OncoSil™ as a viable new treatment for pancreatic cancer and other solid tumours. My complete Leadership team now comprises."

*Dr Ash Soman, Chief Medical Officer
Mr Tom Milicevic, Chief Financial Officer & Company Secretary
Mr Charles Rowland, President, OncoSil Medical USA
Mr David James, Global Head of Manufacturing Operations
Ms Nicole Wilson, Vice President, Regulatory Affairs
Mr Michael Warrener, Global Sales & Marketing Director"*

ENDS

Company	Investor Enquiries	Media
Mr Daniel Kenny CEO & Managing Director E: daniel.kenny@oncosil.com.au T: +61 2 9223 3344	David Allen or John Granger Hawkesbury Partners E: dallen@hawkesburypartners.com T: +61 2 9325 9046	James Moses Mandate Corporate E: james@mandatecorporate.com.au M: +61 420 991 574

About OncoSil

OncoSil is a clinical-stage medical device company seeking to provide a new medical radiation treatment for cancer patients. OncoSil's lead product, OncoSil™ is silicon and phosphorus (p32) beta emitter, able to be implanted by an endoscopically placed catheter in localised solid tumours of patients with pancreatic cancer. Treatment with the OncoSil™ device, known as brachytherapy, is intended to deliver more concentrated and localised beta radiation compared to external beam radiation. OncoSil has conducted four clinical trials with encouraging results on tolerability, safety and efficacy. A CE Mark application for regulatory approval to commercially sell the OncoSil™ device in the EU and other non-US markets is under review with commercial launch planned for 2H2016, subject to approval. An Investigational Device Exemption has also been lodged with the United States Food and Drug Administration to seek approval to conduct a clinical trial of the OncoSil™ device aimed at supporting an FDA approval. Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012, 338,000 people globally were diagnosed with pancreatic cancer. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The estimated world-wide market opportunity for OncoSil™ in pancreatic cancer exceeds \$1b.

Hepatocellular carcinoma (HCC) or liver cancer, is the 6th most common cancer in the world with 782,000 new cases diagnosed in 2012. While hepatocellular carcinoma can be treated by surgery or transplantation, the majority of patients with HCC have disease which is too advanced for surgery and their survival ranges from a few months to two or more years. The value of the hepatocellular cancer market is expected to triple in size to \$1.4b by 2019.

Forward Looking Statements

This document contains certain forward-looking statements, relating to OncoSil's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.